NASDAQ:NBIX - Neurocrine Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $79.89 +1.14 (+1.45 %) (As of 05/26/2019 04:00 PM ET)Previous Close$79.89Today's Range$78.77 - $80.2352-Week Range$64.72 - $126.98Volume573,473 shsAverage Volume943,919 shsMarket Capitalization$7.29 billionP/E Ratio363.14Dividend YieldN/ABeta1.73 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California. Receive NBIX News and Ratings via Email Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NBIX Previous Symbol CUSIP64125C10 CIK914475 Webhttp://www.neurocrine.com/ Phone858-617-7600Debt Debt-to-Equity Ratio0.96 Current Ratio8.79 Quick Ratio8.61Price-To-Earnings Trailing P/E Ratio363.14 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$451.24 million Price / Sales16.16 Cash Flow$0.5101 per share Price / Cash Flow156.63 Book Value$4.48 per share Price / Book17.83Profitability EPS (Most Recent Fiscal Year)$0.22 Net Income$21.11 million Net Margins-7.56% Return on Equity-9.14% Return on Assets-4.21%Miscellaneous Employees585 Outstanding Shares91,287,000Market Cap$7.29 billion Next Earnings Date7/30/2019 (Estimated) OptionableOptionable Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions What is Neurocrine Biosciences' stock symbol? Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX." How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings results on Monday, April, 29th. The company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by $0.07. The business had revenue of $138.40 million for the quarter, compared to the consensus estimate of $136.77 million. Neurocrine Biosciences had a negative net margin of 7.56% and a negative return on equity of 9.14%. The firm's revenue was up 94.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.47) earnings per share. View Neurocrine Biosciences' Earnings History. When is Neurocrine Biosciences' next earnings date? Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, July 30th 2019. View Earnings Estimates for Neurocrine Biosciences. What price target have analysts set for NBIX? 18 brokers have issued 12-month target prices for Neurocrine Biosciences' shares. Their predictions range from $17.07 to $135.00. On average, they expect Neurocrine Biosciences' stock price to reach $103.71 in the next year. This suggests a possible upside of 29.8% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences. What is the consensus analysts' recommendation for Neurocrine Biosciences? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 2 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences. What are Wall Street analysts saying about Neurocrine Biosciences stock? Here are some recent quotes from research analysts about Neurocrine Biosciences stock: 1. According to Zacks Investment Research, "Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes. " (4/30/2019) 2. HC Wainwright analysts commented, "Our price target of $102/share is based on an equally weighted composite of: (a) $103/share, as a 35x multiple of taxed and diluted FY25 GAAP EPS of $8.80 discounted back to and (b) an NPV of $101/share (discount rate 10%, growth rate 2%). We base our valuation on a 20% royalty on sales for Elagolix in endometriosis and uterine fibrosis (probability adjusted). For valbenazine, we include the indication of TD. For opicapone, we include the US revenue (63% goes to 85% POS." (1/30/2019) 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $121 PT on NBIX. Voyager (VYGR, NC) announced a collaboration to develop four of Voyager’s assets, including those for Friedrich’s Ataxia. We believe this deal brings value to both partners, allowing Neurocrine to expand its platform to innovative gene therapy treatments, while it continues to focus on realizing clinical and commercial synergies in movement disorders (and also possibly to expand to additional indications that may be served by Voyager’s platform). We also opine that Voyager benefits from a partner with significantly more resources and expertise in clinical development and commercialization." (1/29/2019) Has Neurocrine Biosciences been receiving favorable news coverage? News headlines about NBIX stock have trended somewhat negative this week, InfoTrie reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neurocrine Biosciences earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. Who are some of Neurocrine Biosciences' key competitors? Some companies that are related to Neurocrine Biosciences include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), BIO-TECHNE (TECH), bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Iovance Biotherapeutics (IOVA) and Denali Therapeutics (DNLI). What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), Celgene (CELG), Sarepta Therapeutics (SRPT), Netflix (NFLX), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD). Who are Neurocrine Biosciences' key executives? Neurocrine Biosciences' management team includes the folowing people: Dr. Kevin C. Gorman, CEO & Director (Age 61)Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62) Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (9.66%), Perceptive Advisors LLC (4.12%), First Trust Advisors LP (1.19%), Pictet Asset Management Ltd. (1.07%), Geode Capital Management LLC (1.04%) and Marshall Wace North America L.P. (0.64%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences. Which major investors are selling Neurocrine Biosciences stock? NBIX stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Perceptive Advisors LLC, OppenheimerFunds Inc., Marshall Wace LLP, GAM Holding AG, First Trust Advisors LP, Frontier Capital Management Co. LLC and Hsbc Holdings PLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View Insider Buying and Selling for Neurocrine Biosciences. Which major investors are buying Neurocrine Biosciences stock? NBIX stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Rockefeller Capital Management L.P., Westfield Capital Management Co. LP, Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Rothschild & Co. Asset Management US Inc., BlueMountain Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Neurocrine Biosciences. How do I buy shares of Neurocrine Biosciences? Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neurocrine Biosciences' stock price today? One share of NBIX stock can currently be purchased for approximately $79.89. How big of a company is Neurocrine Biosciences? Neurocrine Biosciences has a market capitalization of $7.29 billion and generates $451.24 million in revenue each year. The company earns $21.11 million in net income (profit) each year or $0.22 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe. What is Neurocrine Biosciences' official website? The official website for Neurocrine Biosciences is http://www.neurocrine.com/. How can I contact Neurocrine Biosciences? Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected] MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)Community Ranking: 3.9 out of 5 ( )Outperform Votes: 768 (Vote Outperform)Underperform Votes: 221 (Vote Underperform)Total Votes: 989MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: How to interpret a stock’s beta number Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.